Edition:
United Kingdom

Beyondspring - On Track To Submit An NDA To U.S. FDA For Treatment Of Cin


Thursday, 6 Dec 2018 

BeyondSpring Inc ::BEYONDSPRING ANNOUNCES PHASE 3 STUDY 105 OF ITS LEAD ASSET PLINABULIN FOR CHEMOTHERAPY-INDUCED NEUTROPENIA MEETS PRIMARY ENDPOINT AT INTERIM ANALYSIS.BEYONDSPRING INC - HAS NECESSARY DATA TO SUBMIT NDATO CHINA FOOD AND DRUG ADMINISTRATION.BEYONDSPRING - ON TRACK TO SUBMIT AN NDA TO U.S. FDA FOR TREATMENT OF CIN. 

Company Quote

16.33
0.28 +1.74%
9:00pm BST